# 4591 MD

Attorney Docket: NEX61/CIP 1-27.99

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

JANJIC ET A

Ü

SERIAL NO.:

08/897,351

EXAMINER: S. Zitomer

FILED:

JULY 21, 19

ART UNIT: 1634

TITLE:

VASCULAR ENDOTHELIAL

GROWTH FACTOR (VEGF) NUCLEIC ACID LIGAND

**COMPLEXES** 

9 JAN -6 PM 2: 3

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant calls the Examiner's attention to the patent listed on the attached Form PTO-1449, copy enclosed, which may be material to examination of the above-identified application.

## TIME OF TRANSMITTAL

This Information Disclosure Statement is being filed *after* three months of the filing date of this national application or the date of entry of the national stage as set forth in §1.491 in an international application and after the mailing date of the first Office action on the merits but *before* the mailing date of either:

- (1) a final action under §1.113 or
- (2) a notice of allowance under §1.311,

01/04/1999 ANOHAMME 00000223 220277 08897351

01 FC:126 240.00 CH

37 CFR 1.8

**CERTIFICATE OF MAILING** 

Signature:

y Ann Holland

whichever occurs first. The undersigned hereby authorizes the charging of the \$240.00 fee under \$1.97(c) or any deficiency of fees submitted herewith to Deposit Account No. 22-0277.

The filing of this Supplemental Information Disclosure Statement shall not be construed as an admission against interest in any manner. The listed patents and publications are believed of interest herein and consideration and citation as of interest by the Examiner is respectfully requested.

Respectfully submitted,

Margaret M. Wall, #33,462

Swanson & Bratschun, L.L.C.

8400 E. Prentice Ave., Suite 200

Englewood, CO 80111

Telephone: (303) 793-3333

cc: V. Appleby

C:\WPDOCS\NEXAGEN\NEX61CIP\supids4doc.wpd /mah

93 J.M -6 PN 2: 3 GROUP 180